Drugs / Mezagitamab
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05174221 | Aug 2022 → Dec 2025 | glomerulonephritis | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03984097 | Jul 2019 → Mar 2026 | plasma cell myeloma | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03724916 | Nov 2018 → Nov 2021 | systemic lupus erythematosus | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02219256 | Aug 2014 → Apr 2016 | autoimmune disease | Takeda | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04776018 | Apr 2021 → Aug 2023 | refractory plasma cell neoplasm | Takeda | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03439280 | Apr 2018 → Jan 2022 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07613359 | Oct 2026 → Jan 2029 expected | transplant rejection | Takeda | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04278924 | Nov 2020 → Apr 2024 | autoimmune thrombocytopenia | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT04159805 | Jan 2020 → Jul 2022 | generalized myasthenia gravis | Takeda | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06948318 | Aug 2025 → Jul 2029 expected | autoimmune thrombocytopenic purpura | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06963827 | Jul 2025 → Sep 2028 expected | kidney disorder | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06722235 | Feb 2025 → Mar 2028 expected | autoimmune thrombocytopenic purpura | Takeda | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Takeda | Results Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy takeda.com ↗
Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose. |
| 2024-06-24 | Takeda | Results Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia takeda.com ↗
Takeda ( TSE:4502/NYSE:TAK ) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. |
| 2024-03-13 | Takeda | Results Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia takeda.com ↗
Takeda ( TSE:4502/NYSE:TAK ) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP). |
| 2020-11-05 | Takeda | Results Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting takeda.com ↗
Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). |
All press releases naming this drug 9 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mezagitamab | “Mezagitamab is an anti-CD38 antibody that targets plasma cells, plasmablasts, and natural killer cells.” PMID 41950473 ↗ Apr 2026 |
| Known as | TAK-079 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04159805 ↗ |
| Action | Deplete | “coincided with reduction in CD38-expressing cells” PMID 32045493 ↗ Feb 2020 |
| Modality | Monoclonal antibody | “a subcutaneously administered anti-CD38 monoclonal antibody” PMID 40552138 ↗ Sep 2024 |
| Route | Intravenous | “single intravenous (IV) infusion or subcutaneous (SC) administration” NCT02219256 ↗ |
| Route | Subcutaneous | “single intravenous (IV) infusion or subcutaneous (SC) administration” NCT02219256 ↗ |
| Target | CD38 | “anti-CD38 cytolytic antibody TAK-079” PMID 32045493 ↗ Feb 2020 |